NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Overview of attention for article published in Journal of Clinical Oncology, April 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 14 news outlets
blogs: 2 blogs

twitter: 138 X users

Readers on

mendeley: 8 Mendeley

Summary News Blogs X

So far, Altmetric has seen 2 posts from 2 blogs.

NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer

Physician's Weekly, 09 May 2024

WEDNESDAY, May 8, 2024 (HealthDay News) — For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict…

Research reveals potential target for enfortumab vedotin therapy in urothelial carcinoma

news-medical.net, 25 Apr 2024

Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn …

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.